you have data. so now what?
TRANSCRIPT
You have data. So now what?JAMIE JOHNSON, PHARM.D.
CLINICAL PHARMACIST
ANTIMICROBIAL STEWARDSHIP COMMIT TEE CHAIR
Objectives• Understand the rationale for developing an antimicrobial stewardship program
• Review antimicrobial use metrics useful for informing antimicrobial stewardship strategies
• Provide practical examples on employing antimicrobial use data to inform antimicrobial stewardship strategies
DisclosuresNone
Our DataDescending DOT / 1000 PD
Antimicrobials 12-Month Rate
Levofloxacin (all) 136.94
Ceftriaxone 120.60
Ciprofloxacin (all) 82.09
Piperacillin-Tazobactam 81.37
Cefazolin 77.37
Azithromycin (all) 63.57
Vancomycin IV 52.67
Azithromycin IV 52.31
SMX-TMP 44.32
Metronidazole (all) 38.87
Days of Therapy per 1000 Patient-Days
Antibiotics ASAP Facility 1* ASAP Facility 2* ASAP Facility 3† ASAP Facility 4* Larger Facility
Ampicillin/Sulbactam 2.30 19.98 23.17 4.48 15.91
Azithromycin 44.40 63.57 73.36 150.75 23.26
Aztreonam 6.70 0.73 0.97 -- 7.86
Cefazolin 58.10 77.37 68.53 10.45 111.25
Cefepime 3.40 -- 15.44 13.43 20.04
Ceftriaxone 109.80 120.60 108.11 291.04 66.53
Ciprofloxacin 9.60 82.09 10.62 68.66 0.34
Clindamycin 13.10 37.78 23.17 11.94 30.27
Daptomycin 10.20 1.09 -- -- 13.56
Levofloxacin 81.60 136.94 90.73 131.34 75.38
Linezolid 0.60 -- 3.86 50.75 12.49
Meropenem/Imipenem/Doripenem 8.00 9.81 8.69 38.81 25.15
Metronidazole 22.70 38.87 14.48 108.96 42.33
Piperacillin/tazobactam 55.30 81.37 54.05 76.12 109.32
SMX/TMP -- 44.32 6.76 37.31 43.37
Vancomycin IV 86.50 52.67 32.82 86.57 131.36
Group 1 -- Broad-spectrum antibacterial agents for hospital-acquired/multi-drug resistant infectionsAntibiotics ASAP Facility 1 ASAP Facility 2 ASAP Facility 3 ASAP Facility 4 Larger FacilityAztreonam 6.70 0.73 0.97 -- 7.86Cefepime 3.40 -- 15.44 13.43 20.04Ceftazidime 3.60 -- -- -- 1.99Imipenem/Meropenem/Doripenem 8.00 9.81 8.69 38.81 25.15Piperacillin/tazobactam 55.30 81.37 54.05 76.12 109.32Total 77.00 91.91 79.15 128.36 164.36
Group 2 -- Broad-spectrum antibacterial agents for community-acquired infectionsAntibiotics ASAP Facility 1 ASAP Facility 2 ASAP Facility 3 ASAP Facility 4 Larger Facility
Cefotaxime -- -- 11.58 -- 0.72
Ceftriaxone 109.80 120.60 108.11 291.04 66.53
Ciprofloxacin 9.60 82.09 10.62 68.66 0.34
Ertapenem 16.10 -- -- 2.99 16.24
Levofloxacin 81.60 136.94 90.73 131.34 75.38
Total 217.10 339.63 221.04 494.03 159.21
Areas for ImprovementFluoroquinolone usage
Cefazolin usage
Piperacillin/Tazobactam usage
Overall antibiotic usage is high
EducationProvided provider education from an ID physician◦ Great way to Kick-off our program
◦ Peer-to-Peer discussion of importance of Antimicrobial Stewardship
◦ Showed physicians our usage data
◦ Will continue with annual provider education on different areas of stewardship
2222 North Lincoln Avenue
York, Nebraska 68467
Date Collected (Specimen) - 01/01/2016 to 12/31/2016 2016 Antibiogram ReportGram Negative Organisms Gram Positive Organisms
Enterobactercloacae complex
(6)Escherichia coli
(137)Klebsiella oxytoca
(10)
Klebsiella pneumoniae ssp pneumoniae (27)
Proteus mirabilis (13)
Pseudomonas aeruginosa (30)
Enterococcus faecalis (22)
Staphylococcus aureus (62)
Staphylococcus epidermidis (24)
Staphylococcus lugdunensis (6)
Streptococcus agalactiae (15)
Susceptible Total Susceptible Total Susceptible Total Susceptible Total Susceptible Total Susceptible Total Susceptible Total Susceptible Total Susceptible Total Susceptible Total Susceptible Total
Amoxicillin/Clavulanic Acid 0% -6 82% -137 80% -10 93% -27 100% -12 3% -30
Ampicillin 52% -137 0% -10 0% -27 92% -13 0% -28 95% -22 100% -15
Aztreonam 83% -6 94% -137 100% -10 96% -27 92% -13
Benzylpenicillin 95% -22 11% -62 0% -24 17% -6 100% -14
Beta-Lactamase 100% -22 11% -62 0% -24 17% -6 100% -13
Cefazolin 0% -6 93% -137 70% -10 89% -27 92% -13 0% -29
Cefepime 100% -6 94% -137 100% -10 96% -27 92% -13 83% -30
Ceftriaxone 83% -6 94% -137 100% -10 96% -27 92% -13 4% -28
Ciprofloxacin 100% -6 68% -137 90% -10 85% -27 54% -13 63% -30 68% -22 52% -62 58% -24 100% -6
Clindamycin 71% -62 71% -24 83% -6 0% -15
ESBL 93% -137 100% -10 96% -27
Ertapenem 100% -6 100% -137 100% -10 100% -27 100% -13
Erythromycin 14% -22 37% -62 38% -24 83% -6
Gentamicin 100% -6 93% -137 100% -10 100% -27 85% -13 79% -29 100% -62 100% -24 100% -6
Gentamicin High Level (synergy) 82% -22
Imipenem 100% -6 100% -137 100% -10 100% -27 100% -13 79% -28
Inducible Clindamycin Resistance 90% -62 83% -24 100% -6
Levofloxacin 100% -6 68% -137 90% -10 85% -27 54% -13 64% -28 68% -22 53% -62 58% -24 100% -6 93% -15
Linezolid 100% -22 100% -62 100% -24 100% -15
Meropenem 100% -6 100% -137 100% -10 100% -27 100% -13 79% -28
Moxifloxacin 68% -38 58% -24 100% -6
Nitrofurantoin 67% -6 95% -137 80% -10 11% -27 0% -13 0% -29 86% -22 98% -62 100% -24 83% -6
Oxacillin MIC 61% -62 46% -24 67% -6
Piperacillin/Tazobactam 80% -5 99% -137 100% -8 100% -27 100% -12 100% -28
Quinupristin/Dalfopristin 100% -38 100% -24 93% -15
Rifampicin 100% -62 100% -24 100% -6
Streptomycin High Level (synergy) 86% -22
Tetracycline 100% -6 78% -137 90% -10 85% -27 0% -13 4% -28 32% -22 98% -62 88% -24 83% -6 13% -15
Tigecycline 100% -22 100% -62 100% -23 100% -15
Trimethoprim/Sulfamethoxazole 100% -6 78% -137 90% -10 100% -27 77% -13 98% -62
Vancomycin 100% -22 100% -62 100% -24 100% -6 100% -13
AntibiogramPublished annually
Good local data to show providers resistance in their patient population
Educate on how to read antibiogram
Point out key changes from year to year
Use to drive standing order antibiotic selections
Standing OrdersBased on syndromes to treat the disease as an entirety
Current standing orders available at York General:◦ Pneumonia
◦ Skin and soft tissue infections
◦ Urinary Tract Infections
◦ Surgical prophylaxis
◦ Sepsis
Pneumonia Standing OrderA lot of York General fluoroquinolone use is driven by CAP
Add duration to antibiotic orders: 5-7 days
* If patient has Community Acquired Pneumonia and normal
renal function, give:
_____ Levofloxacin 750 mg IV every 24 hours.
OR
_____ Rocephin IVPB, every 24 hours (1 gram if greater than
65 years , 2 grams if less than 65 years) AND Zithromax 500
mg IVPB every 24 hours.
Skin And Soft Tissue InfectionsDeveloped standing order
Defined varying forms of cellulitis with diagnostic criteria to avoid broad spectrum antibiotics if not indicated◦ Cellulitis
◦ Cutaneous Abscess
◦ Diabetic foot infections
◦ Necrotizing fasciitis
Need to add duration 5-7 days
Adjusted based upon antibiogram
Skin and Soft Tissue InfectionsCellulitis◦ Oral- Cephalexin or TMP/SMX◦ IV- Cefazolin or Clindamycin◦ MRSA- Vancomycin per pharmacy
Cutaneous Abscess◦ I & D◦ TMP/SMX or Clindamycin or Vancomycin
Diabetic Foot Infections◦ Mild- Cefazolin or Clindamycin◦ Moderate- Ampicillin/Sulbactam◦ Severe- Piperacillin/Tazobactam◦ MRSA- Vancomycin per pharmacy
Necrotizing Fasciitis◦ Surgical intervention◦ Vancomycin + Pip/Tazo + Clindamycin
Urinary Tract InfectionsCreated standing order
Utilized ceftriaxone as 1st-line agent due to resistance to ciprofloxacin in E. coli isolates
Discuss one-on-one with provider if they order fluoroquinolone for UTI
Need to add durations to orders (3-7 days)
Surgical ProphylaxisAudited cefazolin use to determine appropriateness◦ Most in total joint procedures
Currently reviewing all surgical prophylaxis standing orders
Difficult as most surgeons are from out of town
SepsisMost patients only receive 1 dose of antibiotics in our facility
So started with empiric therapy for different sources◦ Unknown source
◦ Abdominal
◦ Urinary Tract
◦ Neutropenic Fever
◦ Pneumonia
Mismatch between current sepsis order set and syndrome order sets so needed aligned
Pharmacist InterventionsAutomatic pharmacokinetic consult on all aminoglycoside and vancomycin orders
Pharmacy to convert all pip/tazo orders to extended-infusion
Renal dose adjustments
Initiating pharmacist review for key antibiotic usage◦ fluoroquinolones, pip/tazo, carbapenems, and vancomycin
Pharmacist TrackingMotivates individuals to complete interventions◦ Educational tool for making interventions
Great way to provide feedback to individuals
Look at interventions and its impact on facility antibiotic use data
Successes and FailuresUtilization of new standing orders needs improvement◦ Staff communication is essential
Increased provider awareness of antibiogram and resistance patterns in the facility
Pharmacy interventions have been well received
Awaiting results from the past 6 months to determine if interventions have been effective
Future ABS ActivitiesCOPD order set
Required clinical staff education◦ Nursing education on obtaining cultures
Provider specific results and feedback
2017 Antibiogram released in January◦ Review standing orders
2017 Antibiotic use data available for comparison
Questions?